Cardiovascular Drugs Practice Questions

Q: Which antihypertensive medication is administered during pregnancy?

Labetalol. **Explanation:** **Labetalol** is the drug of choice for managing hypertension in pregnancy (including pre-eclampsia). It is a non-selective beta-blocker with additional **alpha-1 blocking activity**. This dual action reduces peripheral vascular resistance without causing significant reflex tachycardia or compromising uteroplacental blood flow. It has a proven safety profile and is not associated with significant teratogenicity. **Analysis of Options:** * **Propranolol (Option A):** While sometimes used for thyrotoxicosis in pregnancy, it is generally avoided for hypertension because it is associated with **intrauterine growth restriction (IUGR)**, neonatal hypoglycemia, and bradycardia due to its non-selective nature and lack of alpha-blocking activity. * **Acebutolol (Option B):** This is a cardioselective beta-blocker with intrinsic sympathomimetic activity (ISA). It is not a first-line agent in pregnancy due to limited safety data compared to Labetalol. * **Metoprolol (Option C):** Although it is a cardioselective beta-1 blocker and sometimes used in the second/third trimester, it is considered second-line to Labetalol and Methyldopa. **High-Yield Clinical Pearls for NEET-PG:** * **First-line drugs in Pregnancy:** Labetalol (DOC), Oral Methyldopa (safest long-term), and Nifedipine (long-acting). * **Hypertensive Emergency in Pregnancy:** Intravenous Labetalol or Hydralazine are preferred. * **Absolute Contraindications:** ACE inhibitors and ARBs are **teratogenic** (cause fetal renal dysgenesis and skull defects). Diuretics are generally avoided as they prevent the physiological expansion of plasma volume. * **Magnesium Sulfate (MgSO₄):** The drug of choice for preventing and treating seizures in eclampsia (not for blood pressure control).

Q: Digoxin is not affected in which of the following conditions?

Hepatic disease. **Explanation:** The correct answer is **Hepatic disease** because of the specific pharmacokinetic profile of Digoxin. **1. Why Hepatic Disease is the correct answer:** Digoxin is a polar glycoside that is primarily excreted **unchanged by the kidneys** (approximately 60-80%) via glomerular filtration and tubular secretion (P-glycoprotein). It undergoes minimal hepatic metabolism. Therefore, its clearance and plasma concentration remain largely unaffected in patients with liver dysfunction, making dose adjustments unnecessary in hepatic disease. **2. Why the other options are incorrect:** * **Renal failure:** Since the kidneys are the primary route of elimination, renal impairment significantly decreases digoxin clearance, leading to toxicity. Doses must be calculated based on Creatinine Clearance. * **Electrolyte disturbances:** Digoxin toxicity is highly sensitive to electrolyte levels. **Hypokalemia**, hypomagnesemia, and hypercalcemia potentiate digoxin's effects and increase the risk of life-threatening arrhythmias. * **Myocardial infarction (MI):** In the acute phase of an MI, the myocardium becomes "irritable" and sensitized. Digoxin can further increase myocardial oxygen demand and lower the threshold for arrhythmias in ischemic tissue. **High-Yield Clinical Pearls for NEET-PG:** * **Digitoxin vs. Digoxin:** Unlike Digoxin, *Digitoxin* is primarily metabolized by the liver and is the drug of choice in renal failure (though rarely used now). * **Volume of Distribution:** Digoxin has a very high $V_d$ because it binds strongly to cardiac and skeletal muscle (Na+/K+ ATPase). It is **not** removed by dialysis. * **Antidote:** Digibind (Digoxin-specific Fab fragments) is the specific treatment for toxicity. * **Monitoring:** Therapeutic range is narrow (0.5–2 ng/mL). Toxicity typically presents with GI symptoms (earliest) and xanthopsia (yellow vision).

Q: Which drugs are used for cardiac remodeling in congestive heart failure?

Digoxin. **Explanation** In the management of Congestive Heart Failure (CHF), it is crucial to distinguish between drugs that provide symptomatic relief and those that modify the disease process (remodeling). **Why the Correct Answer is Digoxin:** The question asks which drug is **NOT** used for cardiac remodeling (or implies the exception based on standard pharmacology). **Note:** In standard medical teaching, Digoxin is the classic "exception." While it increases cardiac contractility and provides symptomatic relief, it has **no effect on cardiac remodeling** and does not reduce long-term mortality. It is primarily used for rate control in atrial fibrillation or for patients who remain symptomatic despite optimal medical therapy. **Analysis of Other Options (Disease-Modifying Drugs):** * **ACE Inhibitors (B):** These are the cornerstone of CHF therapy. By inhibiting Angiotensin II, they prevent pathological hypertrophy and fibrosis, significantly reducing mortality. * **Beta Blockers (A):** Drugs like Carvedilol, Metoprolol succinate, and Bisoprolol prevent catecholamine-induced cardiotoxicity and reverse remodeling, improving ejection fraction over time. * **Aldosterone Antagonists (D):** Spironolactone and Eplerenone block the fibrotic effects of aldosterone on the myocardium, reducing collagen deposition and mortality in NYHA Class II-IV heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **Mortality-Reducing Drugs in CHF:** ACEIs/ARBs, Beta-blockers, Aldosterone antagonists, ARNI (Sacubitril/Valsartan), and SGLT2 inhibitors. * **Symptomatic Only:** Digoxin and Diuretics (Furosemide) improve symptoms but do **not** decrease mortality. * **Digoxin Toxicity:** Characterized by xanthopsia (yellow vision) and various arrhythmias; the most common is PVCs, while the most specific is Atrial Tachycardia with AV block.

Q: Tadalafil is contraindicated in?

Chronic stable angina (acute episode). **Explanation:** **Tadalafil**, a selective Phosphodiesterase-5 (PDE-5) inhibitor, is contraindicated in patients experiencing an acute episode of **chronic stable angina** because the standard of care for acute anginal pain is **Nitroglycerin (Organic Nitrates)**. 1. **Mechanism of Contraindication:** PDE-5 inhibitors prevent the breakdown of cGMP, while Nitrates increase cGMP production via nitric oxide. When used together, they cause a synergistic accumulation of cGMP, leading to profound systemic vasodilation and **severe, life-threatening hypotension**, which can precipitate a myocardial infarction. 2. **Incorrect Options:** * **Pulmonary Arterial Hypertension (PAH):** This is actually a primary *indication* for Tadalafil (along with Sildenafil), as it promotes vasodilation in the pulmonary vasculature. * **Active Infections:** There is no direct contraindication for PDE-5 inhibitors in most infections, though caution is advised in severe sepsis due to baseline hypotension. * **Hepatic Dysfunction:** While dose adjustments are required in mild-to-moderate hepatic impairment, it is not an absolute contraindication unless the dysfunction is end-stage/severe. **High-Yield Clinical Pearls for NEET-PG:** * **The "Time Gap" Rule:** Nitrates should not be administered within **24 hours** of Sildenafil/Vardenafil or within **48 hours** of Tadalafil (due to its longer half-life of ~17.5 hours). * **Other Indications:** Tadalafil is also FDA-approved for **Erectile Dysfunction (ED)** and **Benign Prostatic Hyperplasia (BPH)**. * **Side Effects:** Common side effects include headache, flushing, and dyspepsia. A rare but serious side effect is **Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)**.

Q: Which of the following drugs can cause hyperthyroidism?

Amiodarone. **Explanation:** **Amiodarone** is a Class III antiarrhythmic drug with a unique chemical structure containing approximately **37% iodine by weight**. This high iodine content is the primary reason it can induce thyroid dysfunction. **Why Amiodarone is the correct answer:** Amiodarone can cause hyperthyroidism through two distinct mechanisms, collectively known as **Amiodarone-Induced Thyrotoxicosis (AIT)**: 1. **Type 1 AIT (Jod-Basedow Phenomenon):** Excess iodine from the drug acts as a substrate for increased thyroid hormone synthesis in patients with underlying multinodular goiter or latent Graves' disease. 2. **Type 2 AIT:** The drug exerts a direct toxic effect on thyroid follicular cells, causing destructive thyroiditis and the leakage of preformed hormones into the circulation. *Note: Amiodarone can also cause hypothyroidism via the **Wolff-Chaikoff effect**.* **Why the other options are incorrect:** * **Clonidine (A):** An alpha-2 agonist used for hypertension; it does not affect iodine metabolism or thyroid function. * **Hydralazine (C):** A direct vasodilator used in hypertensive emergencies; its most notable side effect is Drug-Induced Lupus Erythematosus (DILE). * **Penicillamine (D):** A chelating agent used in Wilson’s disease; it is associated with nephrotic syndrome and skin changes, but not hyperthyroidism. **High-Yield Clinical Pearls for NEET-PG:** * **Half-life:** Amiodarone has an exceptionally long half-life (~58 days), meaning thyroid toxicity can persist months after discontinuation. * **Other drugs causing Hyperthyroidism:** Lithium (rarely, though more commonly causes hypothyroidism), Interferon-alpha, and Checkpoint inhibitors (e.g., Pembrolizumab). * **Monitoring:** Baseline and periodic Thyroid Function Tests (TFTs) are mandatory for all patients on Amiodarone.

Q: Which of the following Angiotensin II receptor blockers exhibits antiplatelet action?

Losartan. **Explanation:** **Losartan** is unique among Angiotensin II Receptor Blockers (ARBs) because it possesses a distinct pharmacological profile beyond AT1 receptor blockade. 1. **Why Losartan is correct:** Losartan and its active metabolite (E-3174) act as **competitive antagonists of the Thromboxane A2 (TXA2) receptor**. By blocking these receptors on the surface of platelets, Losartan inhibits platelet aggregation and reduces the risk of thrombus formation. Additionally, Losartan is the only ARB that exhibits **uricosuric activity** by inhibiting the URAT1 transporter in the proximal tubule, making it beneficial for hypertensive patients with gout. 2. **Why other options are incorrect:** * **Valsartan, Irbesartan, and Candesartan:** These are "pure" ARBs. While they are highly effective at blocking the AT1 receptor to cause vasodilation and reduce aldosterone secretion, they do not possess the specific molecular structure required to antagonize thromboxane receptors or inhibit uric acid reabsorption. Their primary clinical benefits are limited to blood pressure control, heart failure management, and nephroprotection in diabetes. **High-Yield Clinical Pearls for NEET-PG:** * **Uricosuric ARB:** Losartan (decreases serum uric acid). * **Longest-acting ARB:** Telmisartan (also acts as a partial agonist at PPAR-γ, improving insulin sensitivity). * **Highest affinity for AT1 receptor:** Candesartan. * **Prodrug ARBs:** Candesartan, Olmesartan, and Azilsartan. * **Common Side Effect:** ARBs do not cause a dry cough (unlike ACE inhibitors) because they do not increase bradykinin levels.

Q: Which is the longest-acting beta-blocker?

Nadolol. **Explanation:** The duration of action of beta-blockers is primarily determined by their lipid solubility and metabolic pathway. **Nadolol** is a non-selective beta-blocker characterized by its high water solubility (hydrophilicity). Because it is not metabolized by the liver and is excreted unchanged by the kidneys, it possesses an exceptionally long plasma half-life (approximately 14 to 24 hours). This allows for once-daily dosing, making it the longest-acting conventional beta-blocker. **Analysis of Options:** * **B. Esmolol:** This is the **shortest-acting** beta-blocker. It is an ultra-short-acting $\beta_1$-selective antagonist with a half-life of only 9 minutes due to rapid hydrolysis by red blood cell esterases. It is administered via IV infusion for emergency situations. * **C. Carvedilol:** A combined $\alpha_1$ and non-selective $\beta$-blocker used in heart failure. It has a moderate half-life of about 6–10 hours. * **D. Acebutolol:** A cardioselective beta-blocker with Intrinsic Sympathomimetic Activity (ISA). Its half-life is roughly 3–4 hours, though its active metabolite (diacetolol) lasts longer (8–12 hours), it still does not exceed Nadolol. **NEET-PG High-Yield Pearls:** * **Longest acting:** Nadolol. * **Shortest acting:** Esmolol (used in supraventricular tachycardia and aortic dissection). * **Most lipid-soluble:** Propranolol (crosses BBB, used for tremors and prophylaxis of migraine). * **Least lipid-soluble:** Atenolol and Nadolol (low CNS side effects). * **Beta-blocker with longest half-life among "selective" agents:** Betaxolol.

Q: Flushing with niacin is reduced by all of the following EXCEPT:

PGD2. **Explanation:** Niacin (Nicotinic acid) induces cutaneous flushing primarily through the release of **Prostaglandin D2 (PGD2)** and **Prostaglandin E2 (PGE2)** in the skin. These prostaglandins act on DP1 receptors, causing intense vasodilation. Therefore, PGD2 is the **cause** of the flushing, not a factor that reduces it. **Why the other options are incorrect (Factors that REDUCE flushing):** * **Laropiprant:** This is a selective **DP1 receptor antagonist**. By blocking the receptor where PGD2 acts, it significantly reduces niacin-induced flushing. * **Premedication with Aspirin:** Aspirin is a COX inhibitor. Since flushing is mediated by prostaglandins, taking aspirin 30 minutes before niacin inhibits prostaglandin synthesis, thereby mitigating the side effect. * **Tachyphylaxis:** This refers to the rapid decrease in response to a drug after repeated doses. With continued use of niacin, the flushing response typically diminishes within 1–2 weeks as the skin cells become desensitized. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Niacin:** It inhibits adipose tissue lipolysis by acting on G protein-coupled receptors (HM74A), leading to decreased VLDL and LDL synthesis. * **Lipid Profile:** Niacin is the most effective agent for **increasing HDL levels**. * **Side Effects:** Apart from flushing, niacin can cause **hyperuricemia** (precipitating gout), **hyperglycemia** (caution in diabetics), and **acanthosis nigricans**. * **Pro-tip:** Taking niacin with meals or using sustained-release formulations also helps reduce the intensity of flushing.

Q: What is the most rapid method for relieving the symptoms of angina pectoris?

Nitrates. **Explanation:** **Nitrates** (specifically sublingual Nitroglycerin) are the treatment of choice for the immediate relief of acute angina pectoris. Their rapid onset of action (1–3 minutes) is due to their ability to act as prodrugs that release **Nitric Oxide (NO)**. NO activates guanylate cyclase, increasing cGMP, which leads to dephosphorylation of myosin light chains and subsequent vascular smooth muscle relaxation. The primary therapeutic effect is **venodilation**, which decreases venous return (preload), thereby reducing left ventricular end-diastolic pressure and myocardial oxygen demand. **Why other options are incorrect:** * **Oxygen:** While supplemental oxygen is indicated if the patient is hypoxemic (SpO2 <90%), it does not provide immediate relief of ischemic pain in a stable patient with normal oxygen saturation. * **Ibuprofen:** NSAIDs are generally avoided in ischemic heart disease as they can increase the risk of cardiovascular events and do not address the underlying pathophysiology of myocardial oxygen supply-demand mismatch. * **Barbiturates:** These are sedatives/hypnotics. While they may reduce anxiety, they have no direct effect on coronary blood flow or myocardial oxygen consumption. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Choice:** Sublingual administration bypasses **first-pass metabolism**, ensuring rapid systemic availability. * **Drug of Choice for Prinzmetal Angina:** Nitrates or Calcium Channel Blockers (CCBs). * **Contraindication:** Nitrates must never be given with **Sildenafil** (PDE-5 inhibitors) due to the risk of severe, life-threatening hypotension. * **Tolerance:** Continuous use leads to "Nitrate tolerance"; a 10–12 hour nitrate-free interval is required daily to maintain efficacy.

Q: Colesevelam is a:

Bile acid sequestrant. **Explanation:** **Colesevelam** is a second-generation **Bile Acid Sequestrant** (also known as a bile acid-binding resin). **Mechanism of Action:** These drugs are large, non-absorbable polymers that bind to bile acids in the intestinal lumen, preventing their enterohepatic circulation. This forces the liver to synthesize new bile acids from endogenous cholesterol. To meet this demand, the liver increases the expression of **LDL receptors**, leading to a significant reduction in serum LDL-C levels. **Analysis of Incorrect Options:** * **Option A (HMG-CoA Reductase Inhibitors):** These are the **Statins** (e.g., Atorvastatin). They inhibit the rate-limiting enzyme in cholesterol synthesis. * **Option B (Insulin Secretagogues):** These include **Sulfonylureas** (e.g., Glipizide) and **Meglitinides**, which stimulate the pancreas to release insulin. * **Option D (Alpha-glucosidase Inhibitors):** These are drugs like **Acarbose** and **Voglibose** that delay carbohydrate absorption in the gut. **High-Yield Clinical Pearls for NEET-PG:** 1. **Unique Property:** Unlike older resins (Cholestyramine), Colesevelam has a higher affinity for bile acids, requires a lower dose, and causes fewer GI side effects. 2. **Dual Indication:** Colesevelam is the only bile acid sequestrant also FDA-approved for improving glycemic control in **Type 2 Diabetes Mellitus** (it reduces HbA1c by ~0.5%). 3. **Safety in Pregnancy:** Since they are not absorbed systemically, bile acid sequestrants are often considered the safest lipid-lowering drugs during pregnancy. 4. **Adverse Effect:** They can cause a compensatory rise in **Triglycerides**; therefore, they are contraindicated if baseline TG levels are >300 mg/dL.

Question 1

Which antihypertensive medication is administered during pregnancy?

Accepted Answer

Labetalol

Answer

Propranolol

Answer

Acebutalol

Answer

Metoprolol

Question 2

Digoxin is not affected in which of the following conditions?

Accepted Answer

Hepatic disease

Answer

Electrolyte disturbances

Answer

Renal failure

Answer

Myocardial infarction

Question 3

Which drugs are used for cardiac remodeling in congestive heart failure?

Accepted Answer

Digoxin

Answer

Beta blockers

Answer

ACE inhibitors

Answer

Aldosterone antagonists

Question 4

Tadalafil is contraindicated in?

Accepted Answer

Chronic stable angina (acute episode)

Answer

Pulmonary arterial hypertension

Answer

Active infections

Answer

Hepatic dysfunction

Question 5

Which of the following drugs can cause hyperthyroidism?

Accepted Answer

Amiodarone

Answer

Clonidine

Answer

Hydralazine

Answer

Penicillamine

Question 6

Which of the following Angiotensin II receptor blockers exhibits antiplatelet action?

Accepted Answer

Losartan

Answer

Valsartan

Answer

Irbesartan

Answer

Candesartan

Question 7

Which is the longest-acting beta-blocker?

Accepted Answer

Nadolol

Answer

Esmolol

Answer

Carvedilol

Answer

Acebutolol

Question 8

Flushing with niacin is reduced by all of the following EXCEPT:

Accepted Answer

PGD2

Answer

Laropiprant

Answer

Premedication with aspirin

Answer

Tachyphylaxis

Question 9

What is the most rapid method for relieving the symptoms of angina pectoris?

Accepted Answer

Nitrates

Answer

Oxygen

Answer

Ibuprofen

Answer

A barbiturate

Question 10

Colesevelam is a:

Accepted Answer

Bile acid sequestrant

Answer

HMG Co enzyme inhibitor

Answer

Insulin secretogogue

Answer

Alpha glucosidase inhibitor

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?